99 related articles for article (PubMed ID: 20954334)
1. [Molecular target drugs for malignant lymphoma].
Terui Y
Nihon Rinsho; 2010 Oct; 68(10):1881-8. PubMed ID: 20954334
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. [R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].
Meusers P; Brittinger G
Praxis (Bern 1994); 1998 Jun; 87(23):793-800. PubMed ID: 9654985
[TBL] [Abstract][Full Text] [Related]
4. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology.
Ponce F; Marchal T; Magnol JP; Turinelli V; Ledieu D; Bonnefont C; Pastor M; Delignette ML; Fournel-Fleury C
Vet Pathol; 2010 May; 47(3):414-33. PubMed ID: 20472804
[TBL] [Abstract][Full Text] [Related]
5. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
O'Connor OA
J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030
[TBL] [Abstract][Full Text] [Related]
6. The applicability of the new WHO-EORTC classification of primary cutaneous lymphomas to a single referral center.
Khamaysi Z; Ben-Arieh Y; Izhak OB; Epelbaum R; Dann EJ; Bergman R
Am J Dermatopathol; 2008 Feb; 30(1):37-44. PubMed ID: 18212543
[TBL] [Abstract][Full Text] [Related]
7. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma.
Ko YH; Kim CW; Park CS; Jang HK; Lee SS; Kim SH; Ree HJ; Lee JD; Kim SW; Huh JR
Cancer; 1998 Aug; 83(4):806-12. PubMed ID: 9708949
[TBL] [Abstract][Full Text] [Related]
8. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
10. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
11. [Malignant lymphomas].
Yamaguchi Y; Usui N
Gan To Kagaku Ryoho; 2009 May; 36(5):736-41. PubMed ID: 19461173
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
Drakos E; Rassidakis GZ; Medeiros LJ
Expert Rev Mol Med; 2008 Feb; 10():e4. PubMed ID: 18241520
[TBL] [Abstract][Full Text] [Related]
14. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
15. Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
Kobayashi Y
Jpn J Clin Oncol; 2011 Feb; 41(2):157-64. PubMed ID: 21113055
[TBL] [Abstract][Full Text] [Related]
16. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
Costa LJ
Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
[TBL] [Abstract][Full Text] [Related]
17. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
de Jong D; Balagué Ponz O
J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of response in aggressive T-cell lymphomas.
Foss FM
Cancer J; 2011; 17(2):142-8. PubMed ID: 21427558
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of 304 cases of malignant lymphomas in pathology: study and practice of the WHO classification of lymphoid neoplasms].
Yin HF; Li T; Li JX
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1556-60. PubMed ID: 14642107
[TBL] [Abstract][Full Text] [Related]
20. [The WHO (1997) classification of 370 cases of malignant lymphomas].
He S; Zhang JB; Zhang JG; Yang SY; Han F
Zhonghua Xue Ye Xue Za Zhi; 2003 Oct; 24(10):519-22. PubMed ID: 14690580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
